MCKESSON CORP reported revenue of $105.38B for the period ended 2026-06-30, +7.7% year on year. Net income was $0.61B, a 0.6% net margin on a 3.5% gross margin. The largest revenue line is North American Pharmaceutical at 82% of the total. Free cash flow for the period was $-0.37B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $105.38B | +7.7% |
| Gross profit | $3.69B | — |
| Operating income | $1.32B | — |
| Net income | $0.61B | -21.7% |
| Gross margin | 3.5% | Net margin 0.6% |
| Segment | Revenue | Share |
|---|---|---|
| North American Pharmaceutical | $86.77B | 82.3% |
| Oncology And Multispecialty | $14.22B | 13.5% |
| Medical Surgical Solutions | $2.82B | 2.7% |
| Prescription Technology Solutions | $1.57B | 1.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $101.69B | 96.5% |
| SG&A | $2.26B | 2.1% |
| Tax & other | $0.70B | 0.7% |
| Item | Amount |
|---|---|
| Total assets | $88.33B |
| Total liabilities | $92.19B |
| Shareholders' equity | $-3.86B |
| Equity / assets | -4.4% |
| Operating cash flow | $-0.22B |
| Capital expenditure | $0.15B |
| Free cash flow | $-0.37B |
| Cash conversion (OCF / net income) | -36% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
MDT ・ MRK ・ META ・ MET ・ MTD ・ MGM ・ MCHP ・ MU ・ MSFT ・ MAA ・ MRNA ・ TAP
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies